1. Introduction

Proponents of Direct-to-Consumer (DTC) drug ads maintain that such ads are educational. The FDA is interested in whether paying greater attention to the educational component of an advertisement (i.e., devoting more attention to defining the disease and its manifestations) would help consumers better understand the role drug and device therapy may play in treating that disease.

Regarding the presentation of risk information in DTC ads, the FDA concerned that consumers and healthcare providers may believe that risk information is not being communicated as clearly as benefit information, even though that information is present.

This survey asks your opinions regarding these DTC issues, especially in light of the fact that the American Medical Association has called for the banning of DTC ads.

Your responses are confidential. At the end of the survey, you can access the de-identified up-to-date results.